Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Autism Spectrum Disorder (ASD)

In brief

The purpose of this study was to evaluate the efficacity and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.

Key facts

Study ID
NCT03715153
Run by
Institut de Recherches Internationales Servier
People needed
211
Starts
2018-10-04
Expected to finish
2021-10-26
Last updated by the study team
2023-06-05

Who can join

Age: 2 and older, up to 6. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.